Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau

BACKGROUND: Augmenting the brain clearance of toxic oligomers with small molecule modulators constitutes a promising therapeutic concept against tau deposition. However, there has been no test of this concept in animal models of Alzheimer’s disease (AD) with initiation at a late disease stage. Thus,...

Descripción completa

Detalles Bibliográficos
Autores principales: Brendel, Matthias, Deussing, Maximilian, Blume, Tanja, Kaiser, Lena, Probst, Federico, Overhoff, Felix, Peters, Finn, von Ungern-Sternberg, Barbara, Ryazanov, Sergey, Leonov, Andrei, Griesinger, Christian, Zwergal, Andreas, Levin, Johannes, Bartenstein, Peter, Yakushev, Igor, Cumming, Paul, Boening, Guido, Ziegler, Sibylle, Herms, Jochen, Giese, Armin, Rominger, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6670231/
https://www.ncbi.nlm.nih.gov/pubmed/31370885
http://dx.doi.org/10.1186/s13195-019-0522-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6670231/
https://www.ncbi.nlm.nih.gov/pubmed/31370885
http://dx.doi.org/10.1186/s13195-019-0522-z

Ejemplares similares